EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploring Barriers to Inclusivity: Systematic Analysis of Exclusion Criteria and Potential Bias in Clinical Cancer Trials for Psychiatric and Neurological Conditions in European Protocols

Margherita Dahò iD, Veronica Coppini iD, Maria Vittoria Ferrari, Giulia Ferraris, Virginia Sanchini, Dario Monzani, Roberto Grasso, Chiara Agnello, Giuseppe Badalamenti, Laura Algeri, Gabriella Pravettoni

Psycho-Oncology · 2025

DOI: 10.1002/pon.70182 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Psycho-Oncology, 2025. Verfasst von Margherita Dahò und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychology, Educational Science and Human Movement, University of Palermo, Palermo, Italy. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Breast Neoplasms, Patient Selection, Mental Disorders. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beacon Cancer Care funded by the European Union's EU4Health Program under Grant Agreement Number: 101080005.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cancer clinical trials often employ exclusion criteria that can impact vulnerable populations, particularly individuals with psychological, psychiatric, or neurological conditions.

Aims

This study aimed to analyze the prevalence and nature of exclusion criteria in clinical trials for prostate, breast, and lung cancers.

Methods

The EU Clinical Trials Register identified 51 protocols uploaded between 2022 and 2024. Thematic content analysis categorized exclusion criteria, and the justifications provided, while frequency analysis quantified their prevalence.

Results

After excluding five protocols (two non‐English and three inaccessible), the final dataset comprised 46 protocols: 13 for prostate cancer (22.8%), 24 for breast cancer (42.1%), and 9 for lung cancer (15.8%). Exclusion criteria targeting vulnerable populations were present in 78.3% of protocols, categorized into five themes: psychiatric conditions (24.6%), neurological conditions (22.8%), other psychological conditions (22.8%), legal/guardianship status (5.3%), and unspecified conditions (24.6%). Compliance concerns (39.1%) were the most common justification, followed by informed consent challenges (32.6%), safety risks (13%), drug interference (10.9%), and not in the best interest (4.3%). Notably, 29.1% of protocols lacked justification for exclusions, raising ethical and transparency concerns.

Conclusions

The exclusion of vulnerable populations may limit the inclusivity and generalizability of cancer research. Heuristic biases and systemic practices can potentially influence this. Exploring the role of these factors and considering adaptive trial designs, along with providing detailed justifications for exclusion criteria, could support more equitable and representative clinical research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials as TopicBreast NeoplasmsPatient SelectionMental DisordersLung NeoplasmsProstatic NeoplasmsNervous System DiseasesNeoplasmsHumansMaleFemaleEuropeVulnerable PopulationsInformed ConsentBias

Stichwörter der Autor:innen

OncologyPsycho‐oncologybiascancerclinical trialsdisparitieshealthcareinclusivitymental healthvulnerable population

Autor:innen und Institutionen

  • Department of Psychology, Educational Science and Human Movement, University of Palermo, Palermo, Italy.
  • WeSearch Lab - Laboratory of Behavioral Observation and Research on Human Development, University of Palermo, Palermo, Italy.
  • Applied Research Division for Cognitive and Psychological Science, IEO European Institute of Oncology IRCCS, Milan, Italy.
  • Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Centre for Biomedical Ethics and Law, Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium.
  • Department of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo, Palermo, Italy.

ORCID-Profile: Margherita Dahò, Veronica Coppini

Förderung

  • Beacon Cancer Care funded by the European Union's EU4Health Program under Grant Agreement Number: 101080005

Zitieren

APA

Dahò, M., Coppini, V., Ferrari, M. V., Ferraris, G., Sanchini, V., Monzani, D., Grasso, R., Agnello, C., Badalamenti, G., Algeri, L., & Pravettoni, G. (2025). Exploring Barriers to Inclusivity: Systematic Analysis of Exclusion Criteria and Potential Bias in Clinical Cancer Trials for Psychiatric and Neurological Conditions in European Protocols. Psycho-Oncology. https://doi.org/10.1002/pon.70182

Vancouver

Dahò M, Coppini V, Ferrari MV, Ferraris G, Sanchini V, Monzani D, et al. Exploring Barriers to Inclusivity: Systematic Analysis of Exclusion Criteria and Potential Bias in Clinical Cancer Trials for Psychiatric and Neurological Conditions in European Protocols. Psycho-Oncology. 2025. doi:10.1002/pon.70182

BibTeX
@article{Dah2025,
  author = {Dahò, Margherita and Coppini, Veronica and Ferrari, Maria Vittoria and Ferraris, Giulia and Sanchini, Virginia and Monzani, Dario and Grasso, Roberto and Agnello, Chiara and Badalamenti, Giuseppe and Algeri, Laura and Pravettoni, Gabriella},
  title = {Exploring Barriers to Inclusivity: Systematic Analysis of Exclusion Criteria and Potential Bias in Clinical Cancer Trials for Psychiatric and Neurological Conditions in European Protocols},
  journal = {Psycho-Oncology},
  year = {2025},
  doi = {10.1002/pon.70182}
}
Kostenlos starten →